Roadshow
ACE
Medigen has developed NK cell ex vivo expansion technology to increase NK cell quantity and enhance their ability to kill tumors, providing high-quality NK cell products (Magicell®-NK). We also developed Automated Cell Expansion systems (ACEs) to transform current labor-intensive and high-risk cell manufacturing processes. Medigen aims to advance the concept of point of cell therapy (POCT) /decentralization to clinical and CDMO facilities, making cell therapies more accessible and of higher quality, thereby enabling patients to afford and receive more effective treatments.
Medigen has developed NK cell ex vivo expansion technology to increase NK cell quantity and enhance their ability to kill tumors, providing high-quality NK cell products (Magicell®-NK). We also developed Automated Cell Expansion systems (ACEs) to transform current labor-intensive and high-risk cell manufacturing processes. Medigen aims to advance the concept of point of cell therapy (POCT) /decentralization to clinical and CDMO facilities, making cell therapies more accessible and of higher quality, thereby enabling patients to afford and receive more effective treatments.
- Established 1999
- Company Medigen Biotech Co., Ltd.
- Telephone [02]2653-5200
- Email info@medigen.com.tw
- Address 14 F., No. 3, Park St., Nangang Dist., Taipei City 11503, Taiwan (R.O.C.)
Founded in 1999, Medigen Biotech Co., Ltd. embraces the vision of "Innovation for a Better Life," focusing on cancer treatment and the development of new medicines to enhance human health. The company specializes in various emerging therapeutic approaches, including small molecule drugs, oncolytic virus therapies, and immune cell therapy. Medigen has evolved into a global biopharmaceutical group, encompassing activities in new drug clinical development, biopharmaceutical research platforms, molecular diagnostics, vaccine technology, ophthalmic pharmaceuticals, and cell therapy.